Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
HIMS plunged 17% after the company issued Q4 revenue guidance of $875-895 million, well below the $955.1 million analysts expected. The midpoint of the range, $885 million, sits roughly $70 million under consensus, a gap of about 7%.
The guidance miss comes with a margin warning. Management pointed to rising sales of lower-margin weight-loss drugs and costs tied to international expansion as headwinds. Interpretation: the market appears to be pricing a double hit, with slower top-line growth than expected and a mix shift that dilutes profitability on each dollar of revenue.
The bull case centers on the Peptides+ category, scheduled to launch at month-end. The Motley Fool frames the launch as a potential growth opportunity that could make HIMS attractive to long-term investors despite the near-term pressure. That is the article's view, not a confirmed revenue driver, and no sales targets for the category were supplied.
The setup is a clean split. Near-term numbers are weaker than Wall Street modeled, while the upside narrative rests on a product launch that has yet to generate results.